Rapport CEO Abraham Ceesay (L) and director Reid Huber

Janssen's neu­ro di­vi­sion churns out Rap­port, a new $100M biotech from Third Rock’s clin­i­cal da­ta hunt

A new neu­ro­science biotech is in the works, and it’s al­ready in the clin­ic with an epilep­sy drug born out of John­son & John­son’s Janssen.

Com­ing out of the work of chief sci­en­tif­ic of­fi­cer and for­mer Janssen neu­ro leader David Bredt, Rap­port Ther­a­peu­tics un­veiled it­self Tues­day with a Phase I study for drug-re­sis­tant epilep­sy. The $100 mil­lion Se­ries A fi­nanc­ing should take RAP-219 to mul­ti­ple mid-stage stud­ies in var­i­ous in­di­ca­tions and shut­tle two dis­cov­ery-stage pro­grams to­ward the clin­ic, Third Rock Ven­tures part­ner and Rap­port di­rec­tor Reid Hu­ber told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.